Surgical management and side effects of parotid gland surgery for benign lesions: a retrospective analysis of our experience from 2012 to 2021

Committeri, Umberto; Arena, Antonio; Iaquino, Vincenzo; Salzano, Giovanni; Blasi, Fabio Di; Esposito, Maria; Giovacchini, Francesco; Calvanese, Carlo; Abbate, Vincenzo; Bonavolontà, Paola; Califano, Luigi; Orabona, Giovanni Dell’Aversana

doi:10.1016/j.bjoms.2023.03.011

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The onset of the different complications after parotid gland surgery is related to the surgery performed. As recently described by Committeri et al (2023) [4], regardless of surgical procedure, the most frequent complication is FS, followed in descending order by temporary facial paralysis, wound dehiscence, salivary fistula, pathological scarring, permanent facial paralysis, and recurrence.…”

Section: Introductionmentioning

confidence: 85%

Late Prevalence of Typical and Atypical Symptoms of Frey’s Syndrome after Parotidectomy for Benign Tumor

Marchese,

Rossi,

Settimi

et al. 2024

JPM

View full text Add to dashboard Cite

Background: The treatment of choice for tumors located in the parotid gland is surgery. Nevertheless, postoperative complications are not infrequent. Regardless of the type of surgical procedure, the most common complication is Frey’s syndrome (FS). Traditionally, FS includes unilateral gustatory sweating and flushing of the facial skin lining the parotid compartment. Recent research describes atypical discomfort associated with FS. The aim of this study was to assess the late prevalence and severity of both usual and atypical symptoms after parotidectomy for benign tumors. Methods: We conducted a cross-sectional study involving 86 subjects who underwent superficial parotidectomy at least one year before the study. The questionnaire included the sweating–flushing–itch–paresthesia–pain (SFIPP) Frey scale supplemented by specific questions about symptoms. Results: Sixty-seven out of eighty-six (77.9%) cases reported almost one symptom. The most frequent symptom was itch (36/67—53.7%), followed by pain (35/67—52.2%), while 28/67 (41.8%) subjects complained of atypical symptoms without flushing or sweating. A desire to treat the discomfort was reported by 50/67 (74.6%) subjects. Conclusions: Late postparotidectomy local discomfort is not infrequent and includes both usual and “unusual” symptoms almost equally. Our results suggest the importance of informing patients about the occurrence of the syndrome and the available treatment options during pre- and postoperative counseling.

show abstract

Section: Introductionmentioning

confidence: 85%

Late Prevalence of Typical and Atypical Symptoms of Frey’s Syndrome after Parotidectomy for Benign Tumor

Marchese,

Rossi,

Settimi

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

“…EGFR is expressed in approximately 40–65% of salivary gland cancer cases [ 11 , 12 ]. Therefore, NIR-PIT using the EGFR Affibody–IR700Dye conjugate for SGC may be a better cancer treatment option than conventional treatment approaches such as surgery, chemotherapy, and radiotherapy, which greatly affect the salivary secretion system and facial nerve that passes through the parotid gland [ 13 ]. We expect that it will expand the targeting scope of NIR-PIT for EGFR-positive SGC.…”

Section: Introductionmentioning

confidence: 99%

Near-Infrared Photoimmunotherapy Using a Protein Mimetic for EGFR-Positive Salivary Gland Cancer

Yamaguchi,

Suzuki,

Okada

et al. 2024

IJMS

View full text Add to dashboard Cite

Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy based on a monoclonal antibody (mAb) conjugated to a photosensitizer (IR700Dye). The conjugate can be activated by near-infrared light irradiation, causing necrotic cell death with high selectivity. In this study, we investigated NIR-PIT using a small protein mimetic (6–7 kDa, Affibody) which has more rapid clearance and better tissue penetration than mAbs for epidermal growth factor receptor (EGFR)-positive salivary gland cancer (SGC). The level of EGFR expression was examined in vitro using immunocytochemistry and Western blotting. Cell viability was analyzed using the alamarBlue assay. In vivo, the volume of EGFR-positive tumors treated with NIR-PIT using the EGFR Affibody–IR700Dye conjugate was followed for 43 days. It was found that NIR-PIT using the EGFR Affibody–IR700Dye conjugate induced the selective destruction of EGFR-positive SGC cells and restricted the progression of EGFR-positive tumors. We expect that NIR-PIT using the EGFR Affibody–IR700Dye conjugate can efficiently treat EGFR-positive SGC and preserve normal salivary function.

show abstract

Use of the SMAS Flap in Benign Parotid Gland Surgery: Review and 5 Years Experience

Catalfamo,

Nava,

De Rinaldis

2024

J. Maxillofac. Oral Surg.

View full text Add to dashboard Cite

Surgical management and side effects of parotid gland surgery for benign lesions: a retrospective analysis of our experience from 2012 to 2021

Cited by 4 publications

References 12 publications

Late Prevalence of Typical and Atypical Symptoms of Frey’s Syndrome after Parotidectomy for Benign Tumor

Late Prevalence of Typical and Atypical Symptoms of Frey’s Syndrome after Parotidectomy for Benign Tumor

Near-Infrared Photoimmunotherapy Using a Protein Mimetic for EGFR-Positive Salivary Gland Cancer

Use of the SMAS Flap in Benign Parotid Gland Surgery: Review and 5 Years Experience

Contact Info

Product

Resources

About